The role of angiogenesis in the development of proliferative diabetic retinopathy: Impact of intravitreal anti-VEGF treatment

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Tremolada, Gemma ^a,b   Del Turco, Claudia ^a   Lattanzio, Rosangela ^a   Maestroni, Silvia ^b   Maestroni, Anna ^b   Bandello, Francesco ^a   Zerbini, Gianpaolo ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; DIABETES MELLITUS; DIABETIC RETINOPATHY; HUMAN; LASER COAGULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VISUAL IMPAIRMENT; DRUG ANTAGONISM; RETINA NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; HUMANS; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861035733     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/728325     Document Type: Review

References (80)

1. Narayan K. M. V., Boyle J. P., Geiss L. S., Saaddine J. B., Thompson T. J., Impact of recent increase in incidence on future diabetes burden: U.S., 20052050 Diabetes Care 2006 29 9 2114 2116 (Pubitemid 44871196)
2. Saaddine J. B., Honeycutt A. A., Narayan K. M. V., Zhang X., Klein R., Boyle J. P., Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 20052050 Archives of Ophthalmology 2008 126 12 1740 1747
3. Fong D. S., Aiello L., Gardner T. W., King G. L., Blankenship G., Cavallerano J. D., Ferris F. L. III, Retinopathy in Diabetes Diabetes Care 2004 27 supplement 1 S84 S87
4. Zhang X., Saaddine J. B., Chou C. F., Cotch M. F., Cheng Y. J., Geiss L. S., Gregg E. W., Albright A. L., Klein B. E. K., Klein R., Prevalence of diabetic retinopathy in the United States, 20052008 JAMA-Journal of the American Medical Association 2010 304 6 649 656
5. Klein R., Knudtson M. D., Lee K. E., Gangnon R., Klein B. E. K., The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII. The twentyfive-year progression of retinopathy in persons with type 1 diabetes Ophthalmology 2008 115 11 1859 1868
6. Hovind P., Tarnow L., Rossing K., Rossing P., Eising S., Larsen N., Binder C., Parving H. H., Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes Diabetes Care 2003 26 4 1258 1264 (Pubitemid 36929282)
7. Nordwall M., Bojestig M., Arnqvist H. J., Ludvigsson J., Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes-The Linkping Diabetes Complications Study Diabetologia 2004 47 7 1266 1272 (Pubitemid 39093322)
8. Lutty G. A., McLeod D. S., Merges C., Diggs A., Plouét J., Localization of vascular endothelial growth factor in human retina and choroid Archives of Ophthalmology 1996 114 8 971 977 (Pubitemid 26271463)
9. Nicholson B. P., Schachat A. P., A review of clinical trials of anti-VEGF agents for diabetic retinopathy Graefe's Archive for Clinical and Experimental Ophthalmology 2010 248 7 915 930
10. Shweiki D., Itin A., Soffer D., Keshet E., Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis Nature 1992 359 6398 843 845
11. Miller J. W., Adamis A. P., Aiello L. P., Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy Diabetes/Metabolism Reviews 1997 13 1 37 50 (Pubitemid 27213792)
12. Aiello L. P., Avery R. L., Arrigg P. G., Keyt B. A., Jampel H. D., Shah S. T., Pasquale L. R., Thieme H., Iwamoto M. A., Park J. E., Nguyen H. V., Aiello L. M., Ferrara N., King G. L., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders New England Journal of Medicine 1994 331 22 1480 1487 (Pubitemid 24356306)
13. Robinson G. S., Pierce E. A., Rook S. L., Foley E., Webb R., Smith L. E. H., Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy Proceedings of the National Academy of Sciences of the United States of America 1996 93 10 4851 4856 (Pubitemid 26162840)
14. Tolentino M. J., McLeod D. S., Taomoto M., Otsuji T., Adamis A. P., Lutty G. A., Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate American Journal of Ophthalmology 2002 133 3 373 385 (Pubitemid 34171588)
15. Lu M., Perez V. L., Ma N., Miyamoto K., Peng H. B., Liao J. K., Adamis A. P., VEGF increases retinal vascular ICAM-1 expression in vivo Investigative Ophthalmology and Visual Science 1999 40 8 1808 1812 (Pubitemid 29297158)
16. Barleon B., Sozzani S., Zhou D., Weich H. A., Mantovani A., Marmé D., Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1 Blood 1996 87 8 3336 3343 (Pubitemid 26115364)
17. Miyamoto K., Khosrof S., Bursell S. E., Rohan R., Murata T., Clermont A. C., Aiello L. P., Ogura Y., Adamis A. P., Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition Proceedings of the National Academy of Sciences of the United States of America 1999 96 19 10836 10841 (Pubitemid 29442230)
18. Ishida S., Usui T., Yamashiro K., Kaji Y., Ahmed E., Carrasquillo K. G., Amano S., Hida T., Oguchi Y., Adamis A. P., VEGF164 is proinflammatory in the diabetic retina Investigative Ophthalmology and Visual Science 2003 44 5 2155 2162
19. McLeod D. S., Lefer D. J., Merges C., Lutty G. A., Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid American Journal of Pathology 1995 147 3 642 653
20. Joussen A. M., Poulaki V., Qin W., Kirchhof B., Mitsiades N., Wiegand S. J., Rudge J., Yancopoulos G. D., Adamis A. P., Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo American Journal of Pathology 2002 160 2 501 509 (Pubitemid 34160327)
21. Vander J. F., Duker J. S., Benson W. E., Brown G. C., McNamara J. A., Rosenstein R. B., Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation Ophthalmology 1991 98 10 1575 1579
22. Brucker A. J., Qin H., Antoszyk A. N., Beck R. W., Bressler N. M., Browning D. J., Elman M. J., Glassman A. R., Gross J. G., Kollman C., Wells J. A., Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings Archives of Ophthalmology 2009 127 2 132 140
23. Flynn H. W. Jr., Chew E. Y., Simons B. D., Barton F. B., Remaley N. A., Ferris F. L., Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study: ETDRS report number 17 Ophthalmology 1992 99 9 1351 1357
24. Salam A., Mathew R., Sivaprasad S., Treatment of proliferative diabetic retinopathy with anti-VEGF agents Acta Ophthalmologica 2011 89 5 405 411
25. Abdallah W., Fawzi A. A., Anti-VEGF therapy in proliferative diabetic retinopathy International Ophthalmology Clinics 2009 49 2 95 107
26. Mirshahi A., Roohipoor R., Lashay A., Mohammadi S. F., Abdoallahi A., Faghihi H., Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: A randomized double-masked clinical trial European Journal of Ophthalmology 2008 18 2 263 269 (Pubitemid 351692187)
27. Tonello M., Costa R. A., Almeida F. P. P., Barbosa J. C., Scott I. U., Jorge R., Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study) Acta Ophthalmologica 2008 86 4 385 389
28. Rizzo S., Genovesi-Ebert F., Bartolo E., Vento A., Miniaci S., Williams G., Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR) Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 6 837 842
29. Adamis A. P., Miller J. W., Bernal M. T., D'Amico D. J., Folkman J., Yeo-T. K., Yeo K. T., Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy American Journal of Ophthalmology 1994 118 4 445 450 (Pubitemid 24307211)
30. Cho W. B., Oh S. B., Moon J. W., Kim H. C., Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy Retina 2009 29 4 516 522
31. Mirshahi A., Roohipoor R., Lashay A., Mohammadi S. F., Abdoallahi A., Faghihi H., Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: A randomized double-masked clinical trial European Journal of Ophthalmology 2008 18 2 263 269 (Pubitemid 351692187)
32. Jorge R., Costa R. A., Calucci D., Cintra L. P., Scott I. U., Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (Ibepe study) Retina 2006 26 9 1006 1013 (Pubitemid 44973219)
33. Moradian S., Ahmadieh H., Malihi M., Soheilian M., Dehghan M. H., Azarmina M., Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 12 1699 1705
34. Arevalo J. F., Maia M., Flynn H. W., Saravia M., Avery R. L., Wu L., Eid Farah M., Pieramici D. J., Berrocal M. H., Sanchez J. G., Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy British Journal of Ophthalmology 2008 92 2 213 216 (Pubitemid 351224097)
35. Abdallah W., Fawzi A. A., Anti-VEGF therapy in proliferative diabetic retinopathy International Ophthalmology Clinics 2009 49 2 95 107
36. Krzystolik M. G., Filippopoulos T., Ducharme J. F., Loewenstein J. I., Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy Archives of Ophthalmology 2006 124 6 920 921 (Pubitemid 43877695)
37. Yeh P. T., Yang C. M., Lin Y. C., Chen M. S., Yang C. H., Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy Retina 2009 29 6 768 774
38. Ahmadieh H., Shoeibi N., Entezari M., Monshizadeh R., Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients a randomized clinical trial Ophthalmology 2009 116 10 1943 1948
39. Chalam K. V., Gupta S. K., Grover S., Brar V. S., Agarwal S., Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma European Journal of Ophthalmology 2008 18 2 255 262 (Pubitemid 351692186)
40. Costagliola C., Cipollone U., Rinaldi M., Della Corte M., Semeraro F., Romano M. R., Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: A survey on 23 cases throughout 12-month follow-up British Journal of Clinical Pharmacology 2008 66 5 667 750
41. Lim T. H., Bae S. H., Cho Y. J., Lee J. H., Kim H. K., Sohn Y. H., Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma Korean Journal of Ophthalmology 2009 23 3 188 192
42. Eid T. M., Radwan A., El-Manawy W., El-Hawary I., Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy Canadian Journal of Ophthalmology 2009 44 4 451 456
43. Cheema R. A., Al-Mubarak M. M., Amin Y. M., Cheema M. A., Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy. Prospective randomized study Journal of Cataract and Refractive Surgery 2009 35 1 18 25
44. Takamura Y., Kubo E., Akagi Y., Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery Ophthalmology 2009 116 6 1151 1157
45. Lanzagorta-Aresti A., Palacios-Pozo E., Menezo Rozalen J. L., Navea-Tejerina A., Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: A pilot study Retina 2009 29 4 530 535
46. Adamis A. P., Altaweel M., Bressler N. M., Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals Ophthalmology 2006 113 1 23 28 (Pubitemid 43021723)
47. Gonzlez V. H., Giuliari G. P., Banda R. M., Guel D. A., Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy British Journal of Ophthalmology 2009 93 11 1474 1478
48. Jardeleza M. S. R., Miller J. W., Review of anti-vEGF therapy in proliferative diabetic retinopathy Seminars in Ophthalmology 2009 24 2 87 92
49. Saishin Y., Saishin Y., Takahashi K., Silva R. L. E., Hylton D., Rudge J. S., Wiegand S. J., Campochiaro P. A., VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier Journal of Cellular Physiology 2003 195 2 241 248 (Pubitemid 36384298)
50. Ishida S., Usui T., Yamashiro K., Kaji Y., Amano S., Ogura Y., Hida T., Oguchi Y., Ambati J., Miller J. W., Gragoudas E. S., Ng Y. S., D'Amore P. A., Shima D. T., Adamis A. P., VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization Journal of Experimental Medicine 2003 198 3 483 489 (Pubitemid 36976059)
51. Shen J., Samul R., Silva R. L., Akiyama H., Liu H., Saishin Y., Hackett S. F., Zinnen S., Kossen K., Fosnaugh K., Vargeese C., Gomez A., Bouhana K., Aitchison R., Pavco P., Campochiaro P. A., Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1 Gene Therapy 2006 13 3 225 234 (Pubitemid 43148645)
52. Abdallah W., Fawzi A. A., Anti-VEGF therapy in proliferative diabetic retinopathy International Ophthalmology Clinics 2009 49 2 95 107
53. Brownlee M., The pathobiology of diabetic complications: A unifying mechanism Diabetes 2005 54 6 1615 1625 (Pubitemid 40770750)
54. Avery R. L., Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment Retina 2006 26 3 352 354 (Pubitemid 44318195)
55. Spaide R. F., Fisher Y. L., Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage Retina 2006 26 3 275 278 (Pubitemid 44318179)
56. Thew M., Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin) Clinical and Experimental Optometry 2009 92 1 34 37
57. Minnella A. M., Savastano C. M., Ziccardi L., Scupola A., Sasso P., Falsini B., Balestrazzi E., Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy Acta Ophthalmologica 2008 86 6 683 687
58. Schmidinger G., Maar N., Bolz M., Scholda C., Schmidt-Erfurth U., Repeated intravitreal bevacizumab (Avastin) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation Acta Ophthalmologica 2011 89 1 76 81
59. Torres-Soriano M. E., Reyna-Casteln E., Hernndez-Rojas M., Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy Retinal Cases Brief Reports 2009 3 1 70 73
60. Kuiper E. J., Van Nieuwenhoven F. A., de Smet M. D., van Meurs J. C., Tanck M. W., Oliver N., Klaassen I., Van Noorden C. J. F., Goldschmeding R., Schlingemann R. O., The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy PLoS One 2008 3 7
61. Yeh P. T., Yang C. M., Lin Y. C., Chen M. S., Yang C. H., Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy Retina 2009 29 6 768 774
62. Jonas J. B., Schmidbauer M., Rensch F., Progression of tractional retinal detachment following intravitreal bevacizumab Acta Ophthalmologica 2009 87 5 571 572
63. Arevalo J. F., Maia M., Flynn H. W. Jr., Saravia M., Avery R. L., Wu L., Eid Farah M., Pieramici D. J., Berrocal M. H., Sanchez J. G., Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy British Journal of Ophthalmology 2008 92 2 213 216 (Pubitemid 351224097)
64. Tranos P., Gemenetzi M., Papandroudis A., Chrisafis C., Papadakos D., Progression of diabetic tractional retinal detachment following single injection of intravitreal Avastin Eye 2008 22 6 862 (Pubitemid 351850529)
65. Jalil A., Fenerty C., Charles S., Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication Eye 2007 21 12 1541
66. Jun Lee S., Jun Koh H., Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin) with pars plana vitrectomy Journal of Ocular Pharmacology and Therapeutics 2009 25 2 173 174
67. Gragoudas E. S., Adamis A. P., Cunningham E. T., Feinsod M., Guyer D. R., Pegaptanib for neovascular age-related macular degeneration New England Journal of Medicine 2004 351 27 2805 2816 (Pubitemid 40051904)
68. Roth D. B., King A., Weiss M., Klein D., Systemic adverse events after bevacizumab Ophthalmology 2009 116 6 1226 1226.e1
69. Kumar V., Ghosh B., Raina U. K., Goel N., Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema Acta Ophthalmologica 2010 88 2 e3
70. Wu L., Martnez-Castellanos M. A., Quiroz-Mercado H., Arevalo J. F., Berrocal M. H., Farah M. E., Maia M., Roca J. A., Rodriguez F. J., Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the pan-american collaborative retina study group (PACORES) Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 1 81 87 (Pubitemid 350167096)
71. Mason J. O. III, White M. F., Feist R. M., Thomley M. L., Albert M. A., Persaud T. O., Yunker J. J., Vail R. S., Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection Retina 2008 28 4 564 567 (Pubitemid 351589565)
72. Yang J. C., Haworth L., Sherry R. M., Hwu P., Schwartzentruber D. J., Topalian S. L., Steinberg S. M., Chen H. X., Rosenberg S. A., A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer New England Journal of Medicine 2003 349 5 427 434 (Pubitemid 36910021)
73. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer New England Journal of Medicine 2004 350 23 2335 2342 (Pubitemid 38702844)
74. D'Amico D. J., Pegaptanib sodium for neovascular age-related macular degeneration. Two-year safety results of the two prospective, multicenter, controlled clinical trials Ophthalmology 2006 113 6 992 1001.e6
75. Singerman L. J., Masonson H., Patel M., Adamis A. P., Buggage R., Cunningham E., Goldbaum M., Katz B., Guyer D., Pegaptanib sodium for neovascular age-related macular degeneration: Third-year safety results of the VEGF inhibition study in ocular neovascularisation (VISION) trial British Journal of Ophthalmology 2008 92 12 1606 1611
76. Rosenfeld P. J., Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration New England Journal of Medicine 2006 355 14 1419 1431 (Pubitemid 44511557)
77. Lucentis (Ranibizumab injection) Package Insert. Genentech Corporation
78. Jardeleza M. S. R., Miller J. W., Review of anti-vEGF therapy in proliferative diabetic retinopathy Seminars in Ophthalmology 2009 24 2 87 92
79. De Almodovar C. R., Lambrechts D., Mazzone M., Carmeliet P., Role and therapeutic potential of VEGF in the nervous system Physiological Reviews 2009 89 2 607 648
80. Nishijima K., Ng Y. S., Zhong L., Bradley J., Schubert W., Jo N., Akita J., Samuelsson S. J., Robinson G. S., Adamis A. P., Shima D. T., Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury American Journal of Pathology 2007 171 1 53 67 (Pubitemid 47339226)